Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer

Autor: Manuel Haschke, Christoph Driessen, Florian Strasser, Thomas Wälti, Beat Thürlimann, Markus Joerger, Alexander von Kameke, Holger Barth, Alexander Hoemme, Claudia Lehner, Stephan Krähenbühl, Martin Früh

Publikováno v: Hoemme, Alexander; Barth, Holger; Haschke, Manuel Martin; Krähenbühl, Stephan; Strasser, Florian; Lehner, Claudia; von Kameke, Alexander; Wälti, Thomas; Thürlimann, Beat; Früh, Martin; Driessen, Christoph; Joerger, Markus (2019). Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer chemotherapy and pharmacology, 83(4), pp. 763-774. Springer 10.1007/s00280-019-03783-9

The risk of potential drug-drug interactions (PDI) is poorly studied in oncology. We included 105 patients with advanced non-small-cell lung cancer (NSCLC), 100 patients with advanced breast cancer (BC) and 100 patients of the palliative care unit (P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f309b7bad29964e6950f6e4be5b646d9